Screener
BioLife Solutions BLFS Payments to Acquire in Process Research and Development
Payments to Acquire in Process Research and Development at other companies
Other financials
Where this comes from
Reported directly by BioLife Solutions in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.
The source filing: BioLife Solutions’s 10-K, filed February 26, 2026.
- Filed
- Feb 25, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-012294
| (In thousands) | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Maturities of available-for-sale securities | 34,764 | 18,400 | 52,700 |
| Investment in available-for-sale securities | (114,063) | (18,415) | (27,095) |
| Purchases of intangible assets | — | (300) | — |
| Investment in IPR&D | (10,221) | — | — |
| Investment in convertible promissory note | (2,000) | — | — |
| Proceeds from sale of divested entities | 23,516 | 73,431 | — |
| Payments on divestiture of Global Cooling | — | (13,039) | — |
| Net cash (used in) provided by investing activities | (71,539) | 58,300 | 17,837 |
ITEM 8. CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is BioLife Solutions's payments to acquire in process research and development?
- BioLife Solutions (BLFS) reported payments to acquire in process research and development of $2.56M in Q4 2025.
- What does payments to acquire in process research and development mean?
- Payments to Acquire in Process Research and Development
Ask your AI about BioLife Solutions's payments to acquire in process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude